‘We’re Not There Yet’: CAR T-Cell Therapy for Renal Cell Carcinoma
NASHVILLE, Tenn. — Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here. CAR T-cell therapy is not yet ready for clinical practice, but enrolling patients in the growing number of clinical trials can help […]
Add-On Olaparib Continues to Show Benefit in First-Line Treatment of mCRPC
SAN FRANCISCO — Adding the PARP inhibitor olaparib (Lynparza) to standard-of-care abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (mCRPC) extended median progression-free survival (PFS), according to final results of the double-blind phase III PROpel study reported here. There was also a trend toward an improvement in median overall survival (OS). At the […]